144 filed Jun 24, 2026 at 16:34 ET
BridgeBio Pharma director Randal Scott filed a Form 144 notice of intent to sell 2,196 shares of common stock, with an estimated aggregate market value of approximately $150,711. The shares were acquired via restricted stock units that vested on June 20, 2026. The sale is being conducted under a Rule 10b5-1 trading plan established on June 27, 2025, which mitigates concerns about opportunistic timing. The proposed sale represents a de minimis portion of Scott's holdings relative to the company's $13.6B market cap and is consistent with routine insider diversification.